41306-64-3

Usage

Uses

Used in Pharmaceutical Applications:
2-(5-Bromo-4-oxopentyl)-1H-isoindole-1,3(2H)-dione is utilized as a compound in drug discovery and development due to its unique structure and potential biological activities. Its specific chemical features may contribute to the design of new therapeutic agents, targeting various diseases and conditions.
Used in Research Applications:
In the realm of scientific research, 2-(5-Bromo-4-oxopentyl)-1H-isoindole-1,3(2H)-dione serves as a valuable tool for studying the interactions of its molecular components with biological systems. Its use aids in understanding the mechanisms of action and potential applications in medicinal chemistry.
Used in Organic Synthesis:
2-(5-Bromo-4-oxopentyl)-1H-isoindole-1,3(2H)-dione is employed as a building block in organic synthesis, where its reactivity and structural features can be leveraged to create new organic compounds with specific properties and functions.
Used in Materials Science:
In materials science, 2-(5-Bromo-4-oxopentyl)-1H-isoindole-1,3(2H)-dione may have potential applications in the development of new materials with unique properties. Its incorporation into material compositions could lead to advancements in various material technologies.
Used in Chemical Compound Development:
2-(5-Bromo-4-oxopentyl)-1H-isoindole-1,3(2H)-dione is used as a precursor in the synthesis of other chemical compounds, where its bromine atom and oxopentyl group can be further modified or utilized in the creation of new molecules with specific applications.

Upstream product

• 84461-00-7 1-diazo-5-phthalimido-2-pentanone 
• 186581-53-3 diazomethane 
• 10314-06-4 4-phthalimidobutyryl chloride 
• 3783-77-5 N-(3-oxobutyl)phthalimide 
• 85-44-9 phthalic anhydride 
• 3130-75-4 4-phthalimidobutyric acid 
• 39739-03-2 4-(1,3-dioxo-1,3-dihydroisoindol-2-yl)-butyric acid methyl ester 
• 5891-21-4 5-chloro-2-pentanone 
• 1074-82-4 potassium phtalimide 
• 3197-25-9 2-(4-oxopentyl)isoindole-1,3-dione 
• 7504-49-6 2-(4-diazo-3-oxobutyl)isoindoline-1,3-dione 
• 136918-14-4 phthalimide 

Downstream Products

• 95914-09-3 2-[2-(2-amino-1,3-thiazol-4-yl)ethyl]-1H-isoindole-1,3(2H)-dione hydrobromide 
• 106467-33-8 1-Benzoyl-2-phenyl-3-{3-[2-(tetrahydro-pyrimidin-2-ylideneamino)-thiazol-4-yl]-propyl}-isourea 
• 106467-13-4 N-Benzoyl-N'-[3-(1H-imidazol-4-yl)-propyl]-N''-{3-[2-(tetrahydro-pyrimidin-2-ylideneamino)-thiazol-4-yl]-propyl}-guanidine 
• 102442-31-9 2-(4-dimethylamino-phenylimino)-3-oxo-6-phthalimido-hexanenitrile 
• 521268-88-2 2-[3-(2-phenyl-1H-imidazol-4-yl)-propyl]-isoindole-1,3-dione 
• 1252573-63-9 5-phthalimido-2-oxopentaldehyde bis(4-phenyl-3-thiosemicarbazide) 
• 1252573-64-0 5-phthalimido-2-oxopentaldehyde bis[4-(4-chlorophenyl)-3-thiosemicarbazide] 
• 1298017-13-6 C₂₀H₁₈N₄O₂S 
• 112357-43-4 Homohistamine dipicrate 
• 40546-33-6 3-[imidazol-4⁽⁵⁾-yl]propylamine 

Relevant academic research and scientific papers

Synthesis of New Methanofullerenes with Phthalimide Fragment

Abstract: Bromo- and chloromethyl ketones based on N-phthalyl-substituted amino acids have been synthesized via the Arndt–Eistert reaction. The products [2+1] cycloaddition to the fullerene scaffold has afforded the monoadducts of fullerene C60.

Phthiobuzonum derivative and its preparation and use

The invention relates to a ftibamzone derivative and a preparation method and an application thereof, and belongs to the technical field of ftibamzone medicament synthesis. Pharmacological experiments prove that the ftibamzone derivative of the invention has obvious cytotoxic activity and antiviral activity, and can be used for treating viral diseases such as tumor, herpes, trachoma, and the like.

Synthesis and functional characterization of imbutamine analogs as histamine H3 and H4 receptor ligands

Imbutamine (4-(1H-imidazol-4-yl)butanamine) is a potent histamine H 3 (H3R) and H4 receptor (H4R) agonist (EC50 values: 3 and 66 nM, respectively). Aiming at improved selectivity for the H4R, the imidazole ring in imbutamine was methyl-substituted or replaced by various differently substituted heterocycles (1,2,3-triazoles, 1,2,4-triazoles, pyridines, pyrimidines) as potential bioisosteres. Investigations in [35S]GTPγS binding assays using membranes of Sf9 insect cells expressing the respective human histamine receptor subtype revealed only very weak activity of most of the synthesized hetarylalkylamines at both receptors. By contrast, the introduction of substituents at the 4-imidazolyl ring was most effective regarding H 4R selectivity. This holds for methyl substitution in position 2 and, especially, in position 5. 5-Methylimbutamine (H4R: EC50 = 59 nM, α = 0.8) was equipotent with imbutamine at the hH4R, but revealed about 16-fold selectivity for the hH4R compared to the hH3R (EC50 980 nM, α = 0.36), whereas imbutamine preferred the hH3R. The functional activities were in agreement with radioligand binding data. The results support the hypothesis that, by analogy with histamine, methyl substitution in histamine homologs offers a way to shift the selectivity in favor of the H4R. According to a bioisosteric approach, the imidazole ring in the dual histamine H3/H4 receptor agonist imbutamine (n = 4) was replaced by various five- and six-membered N-heterocycles. Whereas these structural modifications resulted in a reduction or loss of activity at both receptors, 5-methyl substitution at the imidazol-4-yl ring in imbutamine changed the receptor subtype selectivity in favor of the H4R.

Synthesis and antiviral activity of novel 1,3,4-thiadiazine derivatives

A series of novel 1,3,4-thiadiazine derivatives were synthesized via chemical optimization on phthiobuzone. Their anti-herpes simplex virus (HSV) activities in vitro were also tested. Several compounds exhibited more highly potent anti-HSV activity and much higher selectivity index (SI) values than those of phthiobuzone. The most potent anti-HSV compound was 4f, which showed marked inhibition against HSV-1 (IC50=77.04μg/ml) and HSV-2 (IC50=30.00μg/ml). Meanwhile it had low cytotoxicity (CC 50=1000.00μg/ml), resulting in high (SIHSV-1= 12.98, SIHSV-2=33.33, respectively). Furthermore, a computational study for prediction of absorption, distribution, metabolism, excretion (ADME) properties of compound 4f was performed by determination of topological polar surface area, absorption and Lipinski parameters.

Synthesis and antiviral activity of phthiobuzone analogues

A series of phthiobuzone analogs, prepared from potassium phthalimide or phthalandione, have been evaluated for their antiviral activities. Among the candidates, compounds 5j and 5k, which contain the substituted 4-halogenated phenyl ring at N-4′,4″ position, show more potent antiviral activity than phthiobuzone against herpes simplex virus 1 (IC50=8.56 and 2.85 μ/ml, respectively) and herpes simplex virus 2 (IC50=1.75 and 4.11μg/ ml, respectively). Compounds 9c and 9d with a propylene linker between the phthalimide and bisthiosemicarbazone moieties display similar antiviral potency against herpes simplex virus 1 (IC50=2.85 and 4.11 μg/ml, respectively).

INHIBITION OF BIOFILMS IN PLANTS WITH IMIDAZOLE DERIVATIVES

Disclosure is provided for methods of preventing, removing or inhibiting microbial biofilm formation or microbial infection in a plant or plant part thereof, including applying thereto a treatment effective amount of an active compound as described herein

INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE DERIVATIVES

Disclosure is provided for imidazole derivative compounds that prevent, remove and/or inhibit the formation of biofilms, compositions comprising these compounds, devices comprising these compounds, and methods of using the same.

CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF

According to the present invention, a compound represented by the following formula (I) having a superior PPARα, agonist action and concurrently showing a hypolipidemic action can be provided, and further, a compound useful as a synthetic intermediate for the compound can be provided.

COMPOUNDS AND PROCESS PREPARING A SUBSTITUTED OR AN UNSUBSTITUTED 4(5)-(OMEGA-AMINOALKYL)IMIDAZOLE

A process is provided for preparing novel substituted or unsubstituted 4(5)-ω-aminoalkyl)imidazoles of the formula STR1 wherein n is 1 to 6, R 1 is hydrogen or a linear, branched or cyclic, saturated or unsaturated alkyl group having 1-6 C-atoms or a phenyl ring being unsubstituted, or mono-or di-substituted with groups such as lower alkyl, halogen, alkoxy, methylenedioxy or a combination thereof, and R. sub.2 is hydrogen or methyl. The process comprises brominating an ω-phthalimidoalkan-2-one with bromine in anhydrous methanol to a 1-or 3-bromo-ω-phthalimido-alkan-2-one, subjecting said derivative to ring closure with an amidine in N.N-dimethylformamide with potassium carbonate under mild conditions followed by hydrolytic separation of the phthalic residue. Pharmaceutical compounds, compositions and a method of treatment are also provided.

Synthesis and histamine H2-receptor activity of heterocyclic impromidine analogues.

Analogues of the H2-agonist impromidine with unsubstituted or substituted aromatic or non-aromatic heterocycles instead of the 5-methylimidazole group were prepared via the benzoylguanidine method and tested for H2-agonistic and H1-antagonistic activity in the guinea-pig isolated right atrium and ileum, respectively. Compounds with unsubstituted 2- or 3-pyridyl, 2-pyrazinyl, or 5-pyrimidyl thioether portion proved to be about equipotent in the atrium (about 2-4x histamine). Highest potency was found in the 5-chloro-3-pyridylthioethylguanidine 8h, that is about 20 times more potent as an H2-agonist than histamine, corresponding to about 8 times the activity of the unsubstituted parent compound 8g. It is demonstrated by the piperidinyl- and morpholinylalkyl guanidines 8m-o that an aromatic ring is not required in the affinity-conferring moiety of H2-agonists (8n: 1.3x histamine). Replacement of the (5-methylimidazol-4-yl)methylthio group in the H2-antagonist cimetidine by halogenated pyridyl, pyrazinyl and pyrimidinyl thioethers resulted in compounds inactive as H2-antagonists, giving further evidence for differences in the structural requirements of the affinity-conferring portions of H2-agonists and antagonists and their mode of interaction with the receptor protein.